A Single-arm, Open-label, Extension Study to Evaluate the Long-term Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
Phase of Trial: Phase II/III
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Udenafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Dong-A ST
- 10 Jun 2017 Biomarkers information updated
- 15 Apr 2016 Status changed from active, no longer recruiting to completed.
- 15 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.